Suresh Sakkarai Ramalingam MD FACP, FASCO

Oncology•Atlanta, GA

Hematologic Oncology, Thoracic Cancer

Executive Director, Winship Cancer Institute of Emory University

Join to View Full Profile

1365 Clifton Rd NE# WinshipAtlanta, GA 30322
Phone+1 404-778-5961
Fax+1 404-778-5520

Summary

Dr. Suresh Ramalingam is an oncologist based in Atlanta, GA, specializing in hematologic oncology and thoracic cancer. He completed his residency in internal medicine at Wayne State University School of Medicine and his fellowship in hematology and medical oncology at UPMC Medical Education. His clinical expertise includes pancreatic cancer, mesothelioma, lung cancer, thymoma, and hereditary breast/ovarian cancer. Dr. Ramalingam has authored several publications on topics such as treatment strategies for EGFR-mutant non-small-cell lung cancer and the therapeutic efficacy of osimertinib. He is involved in multiple clinical trials, serving as a principal investigator on studies involving low-dose interleukin-2 and pembrolizumab for stage IV non-small cell lung cancer, among others.

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
Kilpauk Medical CollegeClass of 1992

Certifications & Licensure

GA State Medical License 2007 - 2027
PA State Medical License 2000 - 2008
MI State Medical License 1995 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor Start of enrollment: 2004 May 01
Completed
Phase 1
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Oct 13
Completed
Phase 2
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors Start of enrollment: 2005 Jul 01
Completed
Phase 1
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
COMPLETED
PHASE3
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Start of enrollment: 2006 Jun 01
Completed
Phase 2
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2006 Nov 01
Completed
Phase 1
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Terminated
Phase 1, Phase 2
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction Start of enrollment: 2007 Jun 01
Completed
Phase 1
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE1
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies Start of enrollment: 2012 May 01
Withdrawn
Phase 1
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) Start of enrollment: 2018 Jul 19
ACTIVE_NOT_RECRUITING
PHASE3
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 12
Completed
Phase 1, Phase 2
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Start of enrollment: 2019 May 14
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Start of enrollment: 2019 Oct 08
COMPLETED
PHASE3
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2022 Nov 01
RECRUITING
EARLY_PHASE1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling.
Jung Seok Hwang, JiHoon Kang, Jaehyun Kim, Kiyoung Eun, Sophia West
Nature Communications. 2025-10-08
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate ...
Solange Peters, Meredith M Regan, Luis G Paz-Ares, Martin Reck, Hossein Borghaei
Journal of Thoracic Oncology. 2025-10-01
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, Ibiayi Dagogo-Jack, Raymond Esper
Journal of Thoracic Oncology. 2025-10-01

Journal Articles

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative Analysis
Rathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
Targeted Sequencing and Intracranial Outcomes of Patients with Lung Adenocarcinoma Brain Metastases Treated with Radiotherapy
Gabriel L Sica, Matthew J Ferris, Walter J Curran, Shannon Kahn, Suresh S Ramalingam, Pretesh R Patel, Rathi N Pillai, Robert H Press, Jim Zhong, Conor E Steuer, Taofe..., Cancer
Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer
D R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
Join now to see all

Lectures

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
2019 ASCO Annual Meeting - 6/1/2019

Other

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung Cancer
Suresh Ramalingam, MD, Op-Med
https://www.doximity.com/articles/35d1fb9e-f71f-4645-839f-870e7b27ebe0
UpToDate, Wolters Kluwer Health - 2012-10-04

Authored Content

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung CancerOctober 2018

Press Mentions

Improved Outcomes Reported with Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLCOctober 8th, 2025
Editor's Corner—for the First PD-1xVEGf's Sake, Summit Must Submit to Big Pharma, StatSeptember 10th, 2025
Bispecific Fails to Show Advantage in Phase 3 EGFR-Mutated NSCLC TrialSeptember 9th, 2025
Join now to see all

Grant Support

Administrative Supplement: Early Career Cancer Clinical Investigator Award (ECIA)EMORY UNIVERSITY2009–2028
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)EMORY UNIVERSITY2022–2027
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
Emory Clinical Oncology Career Development Award K12 ProgramEMORY UNIVERSITY2019–2025